Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
EYPT

EyePoint

$2.29

0.01 (0.44%)

, NBI

Nasdaq Biotechnology Index

$0.00

(0.00%)

16:24
12/17/18
12/17
16:24
12/17/18
16:24
Hot Stocks
EyePoint added to Nasdaq Biotechnology Index »

EyePoint Pharmaceuticals…

EYPT

EyePoint

$2.29

0.01 (0.44%)

NBI

Nasdaq Biotechnology Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYPT

EyePoint

$2.07

0.03 (1.47%)

17:22
11/28/18
11/28
17:22
11/28/18
17:22
Syndicate
Breaking Syndicate news story on EyePoint »

EyePoint files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYPT

EyePoint

$2.04

-0.03 (-1.45%)

16:22
11/27/18
11/27
16:22
11/27/18
16:22
Hot Stocks
EyePoint names Ron Honig SVP, General Counsel and company secretary »

EyePoint Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCUL

Ocular Therapeutix

$5.30

-0.25 (-4.50%)

, EYPT

EyePoint

$2.16

-0.13 (-5.68%)

07:15
11/13/18
11/13
07:15
11/13/18
07:15
Recommendations
Ocular Therapeutix, EyePoint analyst commentary at H.C. Wainwright »

Ocular Therapeutix now…

OCUL

Ocular Therapeutix

$5.30

-0.25 (-4.50%)

EYPT

EyePoint

$2.16

-0.13 (-5.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 27

    Nov

  • 28

    Dec

EYPT

EyePoint

$2.31

-0.16 (-6.48%)

06:26
11/06/18
11/06
06:26
11/06/18
06:26
Earnings
EyePoint reports Q3 EPS ,(44c) consensus (16c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYPT

EyePoint

$2.31

-0.16 (-6.48%)

16:19
11/05/18
11/05
16:19
11/05/18
16:19
Hot Stocks
EyePoint signs Durasert license agreement with Ocumension »

EyePoint Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

Over a quarter ago
EYPT

EyePoint

$2.67

-0.27 (-9.18%)

04:55
10/22/18
10/22
04:55
10/22/18
04:55
Conference/Events
EyePoint management to meet with B.Riley RBR »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 05

    Nov

EYPT

EyePoint

$2.96

-0.22 (-6.92%)

07:13
10/18/18
10/18
07:13
10/18/18
07:13
Hot Stocks
EyePoint to present Yutiq data at AAO »

EyePoint announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 05

    Nov

EYPT

EyePoint

$3.22

0.165 (5.41%)

06:40
10/15/18
10/15
06:40
10/15/18
06:40
Conference/Events
EyePoint to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 22

    Oct

  • 05

    Nov

EYPT

EyePoint

$3.22

0.165 (5.41%)

06:36
10/15/18
10/15
06:36
10/15/18
06:36
Hot Stocks
EyePoint's Yutiq implant approved by FDA »

EyePoint…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 05

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.